Last reviewed · How we verify
NCT05944757: prp
Compare of PRP Autologous Serum and Autologous Serum by Intrastromal Injection in Different Eye Disease Conditions
NA trial testing PRP plasma rich platelets in PRP in 40 participants. Status unknown.
1 September 2023
Quick facts
| Lead sponsor | Anita Syla Lokaj |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 September 2021 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2024 |
| Sites | 1 location across Kosovo |
Drugs / interventions tested
- PRP plasma rich platelets — full drug profile →
- Autologous serum — full drug profile →
Conditions studied
- PRP — all drugs for PRP →
Sponsor
Anita Syla Lokaj — full company profile →
Who can join
Adults 20 to 70, any sex, with PRP. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Platelet-rich plasma (PRP) is an autologous blood product rich in proteins and growth factors. Its application has been the subject of many studies in the field of ophthalmology to stimulate tissue healing and regeneration. Due to its anatomical features (lack of blood vessels), the cornea is among the most susceptible to damage structures of the eye. Therefore, the study of the impact of various regenerative therapies (autologous blood products, serums, ) on corneal lesions is important not only scientifically, but also practically for ophthalmologist. Numerous reports described the healing effect of PRP on corneal lesions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05944757
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PRP plasma rich platelets
Trials testing the same drug.
- NCT07514234 — Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS · NA · completed
Other recruiting trials for PRP
Currently open trials in the same condition.
- NCT07470359 — Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and With · Phase 2 · recruiting
- NCT06472323 — The Efficacy and Safety of Pulsed Radiofrequency Combined With Platelet-rich Plasma for the Trigeminal Neuralgia · recruiting
- NCT06028009 — PRP Injections for Genitourinary Syndrome of Menopause · NA · active not recruiting
- NCT05412381 — PRP in ACLR to Prevent PTOA · Phase 3 · recruiting
- NCT05279560 — Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05944757 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anita Syla Lokaj
- Last refreshed: 13 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05944757.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing